Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
Hemodialysis Market Size is projected to reach USD 136.84 Billion by 2031, growing at a CAGR of 4.8%: Straits Research
06 déc. 2022 10h15 HE
|
Straits Research
New York, United States, Dec. 06, 2022 (GLOBE NEWSWIRE) -- A hemodialysis is a form of treatment used to remove water and waste from the blood. During kidney failure, dialysis removes wastes such as...
FibroGen to Report Second Quarter 2022 Financial Results
25 juil. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
11 juil. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian...
Fluorescent Immunoassay Market Size, $3.77Bn by 2028, 5.6% CAGR Led by ELISA Segment (56.12% Market Share in 2021): The Insight Partners
27 mai 2022 06h01 HE
|
The Insight Partners
NEw York, May 27, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Fluorescent Immunoassay Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product...
$130.37Bn Hemodialysis and Peritoneal Dialysis Market 6.4% CAGR to 2028 Led by Hemodialysis (86.09% Revenue Share in 2022): The Insight Partners
27 mai 2022 02h47 HE
|
The Insight Partners
New York, May 27, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Hemodialysis and Peritoneal Dialysis Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
23 févr. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical...
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
14 févr. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close....
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RETA
09 févr. 2022 17h15 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between...
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
04 févr. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink...
KidneyDiet App Brings Expert Nutritional Guidance to Those Suffering from Chronic Kidney Disease
25 janv. 2022 08h00 HE
|
Kismetly, Inc.
BOULDER, Colo., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Kismetly Inc., maker of the number one downloaded kidney-health nutrition app to help people manage chronic kidney disease through informed...